MA50908A - Formulations de protéines de fusion vegfr-fc - Google Patents

Formulations de protéines de fusion vegfr-fc

Info

Publication number
MA50908A
MA50908A MA050908A MA50908A MA50908A MA 50908 A MA50908 A MA 50908A MA 050908 A MA050908 A MA 050908A MA 50908 A MA50908 A MA 50908A MA 50908 A MA50908 A MA 50908A
Authority
MA
Morocco
Prior art keywords
vegfr
fusion protein
protein formulations
formulations
fusion
Prior art date
Application number
MA050908A
Other languages
English (en)
Inventor
William J Callahan
Robert Matthew Fesinmeyer
Rahul Rajan Kaushik
Sai Chakradhar Padala
Yael Wexler-Cohen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50908A publication Critical patent/MA50908A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • A61K38/1866Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050908A 2017-11-17 2018-11-16 Formulations de protéines de fusion vegfr-fc MA50908A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587733P 2017-11-17 2017-11-17
US201862618904P 2018-01-18 2018-01-18

Publications (1)

Publication Number Publication Date
MA50908A true MA50908A (fr) 2020-09-23

Family

ID=65041879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050908A MA50908A (fr) 2017-11-17 2018-11-16 Formulations de protéines de fusion vegfr-fc

Country Status (8)

Country Link
US (2) US12156900B2 (fr)
EP (1) EP3709971A2 (fr)
JP (2) JP7536640B2 (fr)
AU (2) AU2018368466B2 (fr)
CA (1) CA3082899A1 (fr)
MA (1) MA50908A (fr)
MX (2) MX2020005170A (fr)
WO (1) WO2019099921A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50908A (fr) 2017-11-17 2020-09-23 Amgen Inc Formulations de protéines de fusion vegfr-fc
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
WO2019173767A1 (fr) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Formulations aqueuses stables d'aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度vegf受容体融合タンパク質を含む製剤
EP3851096A4 (fr) * 2018-09-10 2022-07-06 Samsung Bioepis Co., Ltd. Composition liquide comprenant une protéine
WO2021050687A1 (fr) * 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Formulations aqueuses stables d'aflibercept
AU2020393842A1 (en) 2019-11-25 2022-06-16 The Regents Of The University Of California Long-acting VEGF inhibitors for intraocular neovascularization
KR20220015976A (ko) * 2020-07-31 2022-02-08 (주)셀트리온 안정한 약제학적 제제
CN116867481A (zh) * 2021-02-17 2023-10-10 艾瑞克有限公司 包含Fc结构域的工程化蛋白质构建体的水性组合物
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2025227916A1 (fr) * 2024-04-29 2025-11-06 齐鲁制药有限公司 Composition comprenant de l'aflibercept et un variant de celui-ci, son procédé associé et son utilisation
US12240888B1 (en) * 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses
JP2026054929A (ja) 2024-09-17 2026-03-30 キオクシア株式会社 メモリシステムおよび制御方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
EP1877438A2 (fr) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN103816115B (zh) 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
WO2013096221A1 (fr) 2011-12-21 2013-06-27 Amgen Inc. Variants polypeptidiques fc ayant une liaison améliorée au récepteur de fc néonatal
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
EA201492289A1 (ru) 2012-06-01 2015-05-29 Офтотек Корпорейшн Композиции, содержащие аптамер против pdgf и антагонист vegf
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
CA3001346A1 (fr) 2015-10-16 2017-04-20 Regeneron Pharmaceuticals, Inc. Compositions proteiniques stables
EA202192290A1 (ru) * 2015-12-16 2022-02-28 Ридженерон Фармасьютикалз, Инк. Композиции и способы получения белковых микрочастиц
WO2017129685A1 (fr) * 2016-01-26 2017-08-03 Formycon Ag Formulation liquide d'un antagoniste du vegf
EP3436473A4 (fr) 2016-03-29 2019-10-23 Navya Biologicals Pvt. Ltd. Procédé de purification de protéines de fusion fc
KR101685532B1 (ko) 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2018063963A1 (fr) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CA3043487A1 (fr) 2016-11-21 2018-05-24 Just-Evotec Biologics Inc Formulations d'aflibercecept et leurs utilisations
GEAP202315128A (en) 2016-12-23 2023-02-10 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
WO2019020777A1 (fr) 2017-07-26 2019-01-31 Formycon Ag Formulation liquide d'un antagoniste du vegf
EP3684332A1 (fr) 2017-09-18 2020-07-29 Amgen Inc. Formules de protéines de fusion vegfr-fc
CN107595765A (zh) 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
MA50908A (fr) 2017-11-17 2020-09-23 Amgen Inc Formulations de protéines de fusion vegfr-fc
WO2019099965A1 (fr) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Formulations d'aflibercept contenant un sel de lysine en tant qu'agent de tonicification et leurs utilisations
EP3730126B1 (fr) 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Composition liquide comprenant un antagoniste du vegf
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (fr) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Formulations aqueuses stables d'aflibercept
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度vegf受容体融合タンパク質を含む製剤
EP3851096A4 (fr) 2018-09-10 2022-07-06 Samsung Bioepis Co., Ltd. Composition liquide comprenant une protéine
WO2020087003A1 (fr) 2018-10-26 2020-04-30 Amgen Inc. Formulations comprenant un tampon tris et une protéine
EP3923907B1 (fr) 2019-02-13 2024-09-25 Novaliq GmbH Compositions et procédés pour le traitement de la néovascularisation oculaire
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
WO2021050687A1 (fr) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Formulations aqueuses stables d'aflibercept

Also Published As

Publication number Publication date
WO2019099921A3 (fr) 2019-06-27
JP2024160287A (ja) 2024-11-13
EP3709971A2 (fr) 2020-09-23
WO2019099921A2 (fr) 2019-05-23
AU2024205240B2 (en) 2026-05-14
CA3082899A1 (fr) 2019-05-23
MX2025004779A (es) 2025-05-02
MX2020005170A (es) 2020-10-16
US12156900B2 (en) 2024-12-03
AU2024205240A1 (en) 2024-08-22
US20250082726A1 (en) 2025-03-13
AU2018368466B2 (en) 2024-06-20
JP2021503485A (ja) 2021-02-12
US20200338164A1 (en) 2020-10-29
AU2018368466A1 (en) 2020-06-18
JP7536640B2 (ja) 2024-08-20

Similar Documents

Publication Publication Date Title
EP3880814A4 (fr) Protéine de fusion
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
EP3519442A4 (fr) Protéines de fusion immunomodulatrices
IL262652A (en) Gdf15 fusion proteins and uses thereof
DK3292141T3 (da) Fusionsproteiner
EP3589662A4 (fr) Protéine monovalente inductible de fixation d' antigène
PT3649151T (pt) Proteínas de suporte
MA50657A (fr) Formulations de niraparib
DK3197453T3 (da) Kimært protein
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
MA50174A (fr) Formules de protéines de fusion vegfr-fc
DK3107562T3 (da) P97-ids-fusionsproteiner
EP3344278A4 (fr) Protéines de fusion immunoglobuline-insuline
EP3355931C0 (fr) Conjugués de protéines
EP3437776A4 (fr) Structure de joint
ZA202003845B (en) Fusion proteins
EP3368012A4 (fr) Formulations de lisinopril
EP3801605A4 (fr) Formulation de protéine de fusion stable
DK3464331T3 (da) Stabiliserede præfusions-rsv f-proteiner
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
EP3419651C0 (fr) Formulation de la protéine de fusion naglu améliorée
EP3688037A4 (fr) Protéines de fusion immunomodulatrices
IL280906A (en) Formulations of ag10
EP3463414C0 (fr) Interfaces de protéines